Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.

@article{Lun2017CompleteMR,
  title={Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.},
  author={Yan Lun and Jianjun Yang and Yun-jian Wu},
  journal={Journal of clinical pharmacy and therapeutics},
  year={2017},
  volume={42 6},
  pages={
          786-789
        }
}
WHAT IS KNOWN AND OBJECTIVE The mixed lineage leukaemia (MLL) gene translocations are found in approximately 10% of adults with acute myeloid leukaemia (AML) and are markers of poor prognosis. As the best reported response in relapsed and refractory MLL-rearranged AML is around 40%, reinduction treatment is very challenging for those patients. CASE DESCRIPTION We report a case of relapsed and refractory AML with MLL-AF9, who did not respond to FLAG (fludarabine, cytarabine, granulocyte colony… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Similar Papers

Loading similar papers…